1-[6-(5-cyano-pyridin-3-yl)-imidazo[1,2-a]pyrazin-2-yl]-3-[2-(2-ethyl-2H-tetrazol-5-yl)-ethyl]-urea | 1103859-90-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-[6-(5-cyano-pyridin-3-yl)-imidazo[1,2-a]pyrazin-2-yl]-3-[2-(2-ethyl-2H-tetrazol-5-yl)-ethyl]-urea
• 英文别名: 1-[6-(5-Cyanopyridin-3-yl)imidazo[1,2-a]pyrazin-2-yl]-3-[2-(2-ethyltetrazol-5-yl)ethyl]urea
• CAS: 1103859-90-0
• 化学式: C₁₈H₁₇N₁₁O
• 分子量: 403.406
• InChiKey: CLPZVWYTPVCLEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  152
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLIQUES BICYCLIQUES ET LEUR UTILISATION COMME INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2009010530A1

  公开（公告）日：2009-01-22

  Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

  磷脂酰肌醇（PI）3-激酶抑制剂化合物，其药用盐及其前药；新化合物的组合物，可以单独使用或与至少一种额外治疗剂联合使用，携带药用载体；新化合物的用途，可以单独使用或与至少一种额外治疗剂联合使用，用于预防或治疗由生长因子、蛋白质丝氨酸/苏氨酸激酶和磷脂激酶异常活性所特征化的增殖性疾病。
• Organic Compounds
  申请人：Bruce Ian

  公开号：US20100197682A1

  公开（公告）日：2010-08-05

  Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

  磷脂酰肌醇（PI）3-激酶抑制剂化合物及其药学上可接受的盐和前药；新化合物的组合物，可以单独使用或与至少一种额外治疗剂联合使用，与药学上可接受的载体；以及新化合物的用途，可以单独使用或与至少一种额外治疗剂联合使用，用于预防或治疗由生长因子、蛋白质丝氨酸/苏氨酸激酶和磷脂酰肌醇激酶异常活性所特征的增殖性疾病。
• BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP2178868A1

  公开（公告）日：2010-04-28
• US8053574B2
  申请人：——

  公开号：US8053574B2

  公开（公告）日：2011-11-08